Delivery Order HHSN261201200035I-HHSN26100006

This federal contract award is for Task Order 1A of the Cancer Trials Support Unit (CTSU) contract, a $548 million Indefinite Delivery Vehicle (IDV) with the National Cancer Institute (NCI). The prime contractor is PPD Development LP, a global contract research organization (CRO) and subsidiary of Thermo Fisher Scientific, that specializes in providing comprehensive clinical trial, research, and regulatory support services to federal agencies. The Task Order 1A project is a $2,245 cost-sharing...

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Delivery Order contract to the University of Arizona, doing business as the Arizona Board of Regents, to provide core infrastructure support for the Cancer Prevention Agent Development Program. The $1,535,496.00 contract has a performance period ending on September 22, 2023 and does not utilize a set-aside designation. This Delivery Order is part of the larger Cancer Prevention Agent...

This is a federal contract award to the University of Arizona, doing business as the Arizona Board of Regents, by the National Cancer Institute (NCI) under the Cancer Prevention Agent Development Program 2012-2017. The award has a ceiling value of $2,924,327.60 and is for research and development services related to the core infrastructure support for the NCI's cancer prevention agent development program's early phase clinical research. The contract is a delivery order and does not have a...

This federal contract award from the National Cancer Institute (NCI) is a delivery order under the NIH Cancer Trials Support Unit (CTSU) Indefinite Delivery Vehicle (IDV). The $128,414.63 award was issued to PPD Development LP, a global contract research organization (CRO) that provides comprehensive clinical trial and research support services to federal agencies. The contract supports the Cancer Trials Support Unit program, which provides clinical trial management and research services to...

This is a firm fixed-price delivery order under Contract HHSN261201200017I|HHSN26100013, awarded by the National Cancer Institute, a civilian agency of the Department of Health and Human Services, to Palladian Partners, Inc., a for-profit communications and marketing firm. The $250,167.73 contract is for TASK 13-ADVOCATE ENGAGEMENT AND OAR SUPPORT, which involves providing strategic communications, outreach, and meeting planning services. Palladian Partners is a subsidiary of the Altarum...

This federal contract award is for the National Cancer Institute's Cancer Prevention Agent Development Program. The prime contractor is The University of Texas M.D. Anderson Cancer Center, a comprehensive cancer research and treatment center. The contract has a ceiling value of $4,248,160.62 and does not use a set-aside designation. The contract supports early phase clinical research, with the objective of developing cancer prevention agents. It includes subcontracts with several universities...

The Department of Health and Human Services, National Institutes of Health, National Cancer Institute awarded a $709,235 Delivery Order contract to the University of Wisconsin System for core infrastructure support under the Cancer Prevention Agent Development Program 2012-2017 contract. This Cost-No-Fee contract does not have a set-aside designation and was awarded on September 23, 2014, with a completion date of September 23, 2015. The University of Wisconsin System, through its University...

<p>This is a $994,198.78 cost-plus-fixed-fee definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Precision For Medicine (TX), Inc. on September 20, 2013. The contract is for research and development in biomedical (basic research) and has a period of performance through September 19, 2015. The contract is designated as a total small business set-aside.</p>

This is a delivery order under the Preclinical Agent Development Assays 2012-2016 Indefinite Delivery Contract (IDC) awarded by the National Cancer Institute (NCI) to the Weill Medical College of Cornell University. The order is for $614,987.25 and covers preclinical in vitro and in vivo agent development assays and blood-based biomarkers of obesity-induced breast inflammation. This work supports the NCI's PREVENT Cancer Preclinical Drug Development Program, which aims to transition cancer...

This is a $819,519.17 cost-reimbursement delivery order awarded by the National Cancer Institute, a civilian agency of the U.S. Department of Health and Human Services, to the University of Oklahoma Univ Of Oklahoma Health Sciences Center Division. The order is placed under the Preclinical Agent Development Assays 2012-2016 contract vehicle and supports the development of inhibitors for MPGES-1 and 5-LOX proteins for use as colon cancer chemopreventive agents. This work is part of the agency's...